FDA pan­el large­ly op­pos­es ex­pand­ing use of Lil­ly, Boehringer's SGLT2 in­hibitor to type 1 di­a­bet­ics

Last week, Eli Lil­ly and part­ner Boehringer In­gel­heim re­jigged the terms of their 2011 di­a­betes pact that nur­tured the de­vel­op­ment of their block­buster Jar­diance fran­chise. Akin to man­u­fac­tur­ers of ri­val SGLT2 drugs, the com­pa­nies are work­ing to ex­pand­ing the use of their type 2 di­a­betes drug to reach a broad­er group of pa­tients. On Wednes­day, an ex­pert pan­el to the FDA re­sist­ed that ef­fort by large­ly vot­ing against their quest to mar­ket the drug in type 1 di­a­bet­ics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.